Over the past decade, new drugs, i.e., biologic therapies like anti-TNF therapies, have been studied and introduced as a treatment for IBD for patients not responding to the drugs used or because of harmful side effects associated with the traditional therapies, have proved to be beneficial but refractory disease and a substantial number of non-responders still pose as a significant challenge. Here, TNF is linked to inflammatory bowel disease.